Keywords

- MALAT1
- Tenogenic differentiation
- miR-378a-3p

Abstract

Tendinopathy is a type of chronic injury caused by repeated pulling. Previous studies have reported that long non-coding RNA MALAT1 (MALAT1) regulates a variety of genes affecting bone metabolism. This study aimed to explore the role of MALAT1 in tendon injury in vivo and in vitro. Human tendon-derived stem cells (TDSCs) were treated with TGF-β1. Eighteen Sprague-Dawley rats were used to establish the tendinopathy animal model. Sirius Red staining and colorimetric assays were conducted to analyze the collagen content. RT-qPCR was performed to measure the mRNA levels. Western blotting was performed to measure the MAPK1 protein levels. Additionally, hematoxylin and eosin (HE) and immunohistochemical staining were used to analyze the cell number and the content of collagen type 1 and Thbs, respectively. MALAT1 expression was upregulated in TGF-β1 treated TDSCs, and MALAT1 knockdown downregulated Scleraxis, Mohawk homeobox, Collagen 1A1, Fibromodulin, Matrix metalloproteinase 3, and Thrombospondin 4 in TGF-β1 treated TDSCs. Bioinformatics analysis showed that miR-378a-3p was the target of MALAT1 and MAPK1, and dual-luciferase reporter assay indicated that both MALAT1 and MAPK1 could bind to miR-378a-3p. Furthermore, miR-378a-3p knockdown reversed the effect of si-MALAT1, whereas overexpression of MAPK1 reversed the effect of the miR-378a-3p mimic. Finally, MALAT1 expression was downregulated in tendinopathy rats, and MALAT1 overexpression healed tendon injury in them. MALAT1 regulated the tenogenic differentiation of TDSCs by regulating the miR-378a-3p/MAPK1 axis. Our results therefore indicate that targeting the MALAT1/miR-378a-3p/MAPK1 axis may be a promising avenue for the treatment of tendinopathy.

Highlights

- MALAT1 was significantly upregulated in TGFβ1-treated TDSCs.
- Knockdown of MALAT1 suppressed tenogenic differentiation.
- MALAT1 functioned as a sponge for miR-378a-3p.
Introduction

Tendinopathy is a type of chronic injury caused by repeated pulling and is characterized by motion-related pain, increased sensitivity of the local Achilles tendon, and changes in imaging of the tendon [1]. Previously, tendinopathy was thought to be a simple inflammatory reaction, and was therefore called "tendinitis". However, recent histopathological studies have shown that the pathological process of tendinopathy involves tendon degeneration [2], and its specific pathophysiological changes need to be clarified in detail. Local stem cells are known to promote the repair of damaged tissues [3]. In 2007, Bi et al. [4] first identified a cell type different from other mesenchymal stem cells in mouse and human tendons, named the tendon stem cell (TSC). Compared to tendon cells, TSCs exhibit better cell proliferation and collagen formation abilities. TSCs differentiate into tendon cells under certain physiological conditions, and secrete extracellular matrix (ECM) components [5,6]. The differentiation of the tendon and the formation of the tendon ECM can effectively heal tendon injury. TSCs have been reported to directly participate in the repair of damaged tendons and improvement of the biomechanical properties of diseased tendons [7]. Additionally, TSCs differentiate into adipocytes, osteocytes, and chondrocytes under certain pathological conditions. Therefore, promoting the differentiation of TSCs into tenogenic cells and inhibiting their non-tenogenic differentiation under pathological conditions is an effective strategy for the treatment of tendon injury.

In recent years, there have been rapid strides in research on long non-coding RNAs (lncRNAs). lncRNAs are RNA transcripts with a length of more than 200 nucleotides (nt) [8,9], and have been reported to be involved in various biological processes. Emerging evidence indicates that lncRNAs are closely associated with cell differentiation and tissue regeneration [10]. However, studies on the role of lncRNAs in tenogenic differentiation are limited. In 2003, lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was first discovered in a study on non-small cell lung cancer (NSCLC) and has attracted attention of researchers in recent years [11]. MALAT1 is approximately 8000 nt long, and is located on chromosome 11q13 [12]. Previous studies have reported that MALAT1 regulates a variety of genes affecting bone metabolism, such as upregulation of osterix protein expression to promote osteoblast proliferation and differentiation, and downregulation of RANKL expression to inhibit osteoclast activation [13,14]. However, the mechanisms underlying the role of MALAT1 in tendinopathy are still unclear. MicroRNAs (miRNAs) are small non-coding RNAs with a length of 18–22 nt [15], and perform their biological functions by competing with lncRNAs [16]. For instance, MALAT1 promotes osteoblast growth by regulating the miR-34c/SATB2 axis [17]. Zhang et al. also found that MALAT1 participates in proliferation, apoptosis, and ECM degradation, by regulating the miR-150-5p/AKT3 axis [18]. A previous study showed that miR-378a can be used as a novel biomarker for the diagnosis of tendon injury [19].

Therefore, in this study, we aimed to explore the role of MALAT1 in tendinopathy both in vivo and in vitro. We hypothesized that MALAT1 promotes tenogenic differentiation by regulating the miR-378a-3p/MAPK1 axis.

Materials and methods

Animal experiments

Eighteen Sprague-Dawley rats (210 ± 11.2 g) were provided by the Laboratory Animal Center of the Guangdong Medical University, China. The specific grouping was as follows: control group (CON), collagenase I group (Model), and Model+MALAT1 overexpression group (oe-MALAT1). In the Model group, 2.5% pentobarbital sodium was administered to anesthetize the rats. Next, 30 μL of collagenase I was injected into the bilateral Achilles tendons of the rats. Adenoviruses containing the MALAT1 overexpression vector (RiboBio, Guangzhou, China) were injected into the model group mice via the tail vein to overexpressed the MALAT1 levels. After six weeks, the rats were euthanized and the patellar tendons were collected for further analysis.

HE staining

Patellar tendons were fixed in 4% paraformaldehyde for 24 h [20]. The tissues were then embedded in
paraffin and sectioned. After washing with PBS, the sections were stained with hematoxylin and eosin. Finally, the sections were observed under a microscope (Leica Microsystems, Germany).

**Immunohistochemistry**

The sections were hydrated using different concentrations of ethanol [21]. Bovine serum albumin (1%) was used for blocking. The sections were then incubated with anti-collagen I (Abcam, UK) and anti-thrombospondin 4 (THbs4) (Abcam) overnight. On the second day, the sections were treated with donkey anti-rabbit HRP-binding secondary antibody (Abcam) for 1 h, followed by addition of 3,39-diaminobenzidine tetrahydrochloride. Finally, ImageJ software was used to measure the percentage of stained area relative to the total area under a microscope (Leica Microsystems).

**Cell culture and treatment**

Human tendon-derived stem cells (TDSCs) were provided by cell bank of the Chinese Academy of Sciences (Shanghai, China). TDSCs were cultured in low-glucose DMEM (10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin) at 37°C and 5% CO₂. For tenogenic differentiation, TDSCs were treated with 5 ng/ml TGFβ1. When cell fusion reached 70%, the cells were collected for subsequent experiments.

**Cell transfection**

siRNA targeting MALAT1 (si-MALAT1 1#, si-MALAT1 2#) and siRNA negative control (si-nc), MALAT1 overexpression plasmid (oe-MALAT1) and its empty vector (oe-nc), miR-378a-3p mimic (mimic) and its negative control (nc-mimic), miR-378a-3p inhibitor (inhibitor) and its negative control (nc-inhibitor), and MAPK1 overexpression plasmid (MALAT1) and its empty vector (vector), were purchased from GenPharma. Lipofectamine 3000 (Invitrogen) was used to transfect the TDSCs, according to the manufacturer’s instructions [22]. Sirius Red staining

Sirius Red staining and colorimetric assays were performed to analyze the collagen content [23]. Briefly, TDSCs were washed and fixed in 4% paraformaldehyde for 10 min. The TDSCs were then stained with 1 mL saturated picric acid solution with 0.1% Sirius Red. Subsequently, 0.1% NaOH and absolute methanol were added to elute the color. Finally, a spectrophotometer (BioTek Instruments, USA) was used to quantify the red color at 540 nm.

RT-qPCR

Total RNA from the cells and tissues was separated using TRIzol® (Thermo Fisher Scientific, MA, USA). Then, the Prime Script RT Master Mix kit (Takara, Dalian, China) was used to synthesize cDNAs. PCR was performed using a miScript SYBR Green PCR Kit (Takara) on a 7900 Real-Time PCR System (Thermo Fisher Scientific, MA, USA). The reaction conditions were as follows: 95°C, 5 s; 45 cycles of 95°C, 5 s; 60°C, 1 min; 95°C, 5 s; 60°C, 1 min. The relative expression of target genes was calculated using the 2^−ΔΔCt method [24]. GAPDH or U6 was used as a housekeeping gene control. The primer sequences were as follows:

- MALAT1, forward primer: 5’-TCTTAAGGTC AAGAAGTGTCAG-3’, reverse primer: 5’-GTGG CGATGGCAGAA-3’;
- Scleraxis (Scx), forward primer: 5’-CTGGCCT CACGCTATCTCTG-3’, reverse primer: 5’- GTCAACGTTTTGTCAACCT-3’;
- Mohawk homeobox (Mkx), forward primer: 5’- CTCGCAGATGAGCTAGTG-3’, reverse primer: 5’-TGGCTGTGAAAGGTATTCTT-3’;
- Collagen 1A1 (Col1a1), forward primer: 5’- GAGGCCAAGACGAGAAATC-3’, reverse primer: 5’-CAGATCAGTCGACAGA-3’;
- Fibromodulin (Fmod), forward primer: 5’-AT TGTTG GCCACTACCTC-3’, reverse primer: 5’- GTCAGAGGCTGTAGGCTCATA-3’;
- Matrix metalloproteinase 3 (Mmp3) forward primer: 5’-CGGTTCGGCGCTGCAAGT-3’, reverse primer: 5’-CGCCAAAAGTGCCGTCCTT-3’;
- Thrombospondin 4 (Thbs4), forward primer: 5’- TGCTGCCGTCCTGACAGA-3’, reverse primer: 5’-GTTTAAGCGTCCCATCAGTA-3’;
miR-378a-3p, forward primer: 5’-GCGCACTGGACTTGGAGTC-3’, reverse primer: 5’-GCAGGGTCCAGGCTATTC-3’;
Mitogen Activated Protein Kinase1 (MAPK1), forward primer: 5’-TGAGCGACCTTCTCAGTC-3’, reverse primer: 5’-AGCCCAATGACGTTCCTC
ATGC-3’;
GAPDH, forward primer: 5’-TGTGTCCGTCGTGGATCTGA-3’, reverse primer: 5’-CCTGCTCATCCACCCTTCTTGA-3’;
U6, forward primer: 5’-GCTTCGGCAGCTATACTAA-3’, reverse primer: 5’-AACGCTTACGAATTTGCGT-3’.

**Bioinformatics analysis**
The target miRNA of MALAT1 was predicted using online Starbase software (http://hopper.si.edu/wiki/mmti/Starbase). The target of miR-378a-3p was predicted using TargetScan software (http://www.targetscan.org/vert_72/) and MiRDB software (http://mirdb.org/index.html) [25].

**Dual-luciferase reporter assay**
The wild-type (WT) and mutant (MUT) 3’-UTR regions of MALAT1 or MAPK1 were co-transfected into TDSCs. After 48 h of conventional culture, fluorescence was determined using a dual-Glo luciferase assay system (Promega, Madison, WI, USA) [26].

**Statistical analysis**
Data were analyzed using SPSS (version 22.0, SPSS, Chicago, IL, USA) and expressed as mean ± standard deviation. Each experiment was repeated three times. Student’s t-test was used to analyze the differences between two groups, one-way ANOVA was used to analyze the differences among multiple groups. Statistical significance was set at p < 0.05.

**Results**

**Characterization of TDSCs**
TDSCs have a typical fusiform morphology and can differentiate into adipocytes, osteoblasts and chondrocytes (Figure 1(a)). As shown in Figure 1(b and C, the expression levels of positive markers CD90, CD106 and CD44 were 99.54%, 99.73% and 98.79%, respectively, and those of negative markers CD105 and CD11B were 1.18% and 2.97%, respectively.

![Figure 1](image_url)

**Figure 1.** Characterization of TDSCs. (a) Morphology of TDSCs and the potential of multilineage differentiation of TDSCs. (b) Surface markers including CD90, CD105, CD44, CD106 and CD11B measured by flow cytometry assay.
MALAT1 was significantly up-regulated in the TGFβ1 treated TDSCs

We used 5 ng/ml TGFβ1 to induce tenogenic differentiation. The results showed that TGFβ1 promotes the production of collagen, and can therefore successfully induce tenogenic differentiation in TDSCs (Figure 2(a)). We also found that MALAT1 expression was upregulated in TGFβ1 treated TDSCs on days 0, 3, 7, and 10 (Figure 2(b)), and reached its highest level on day 7; therefore, we treated TDSCs with TGFβ1 for 7 days in subsequent experiments.

Knockdown of MALAT1 suppressed tenogenic differentiation

We further explored the role of MALAT1 in tenogenic differentiation. We designed an siRNA to downregulate MALAT1 expression. MALAT1 expression was dramatically downregulated after si-MALAT1 transfection (Figure 3(a)). Furthermore, MALAT1 knockdown decreased TGFβ1 induced collagen production (Figure 3b-c)). Next, we determined the expression of tenogenic markers and found that, compared with the NC group, the expression levels of Scx, Mxk, Fmod, Col1a1, Mmp3, and Thbs4 were significantly increased. Knockdown of MALAT1 reversed these effects (Figure 3(d-i)).

MALAT1 functions as a sponge for miR-378a-3p

The binding sites of MALAT1 and miR-378a-3p were predicted using the online database Starbase 3.0 (Figure 4(a)). Dual-luciferase reporter assay showed that the miR-378a-3p mimic significantly inhibited luciferase activity in TDSCs transfected with WT-MALAT1 instead of MUT-MALAT1 (Figure 4(b)). In addition, knockdown of MALAT1 upregulated the expression of miR-378a-3p, whereas overexpression of MALAT1 downregulated the expression of miR-378a-3p (Figure 4(c)). The expression of miR-378a-3p was down-regulated in the TGFβ1 group (Figure 4(d)).

Knockdown of miR-378a-3p reversed the effect of si-MALAT1

Subsequently, we designed a miR-378a-3p inhibitor to downregulate miR-378a-3p expression. The expression of miR-378-3p markedly decreased after transfection with the inhibitor (Figure 5(a)). Furthermore, we found that knockdown of miR-378a-3p reversed the effects of si-MALAT1 on collagen production (Figure 5(b-c)) and the expression of Scx, Mxk, Fmod, Col1a1, Thbs4, and Mmp3 (Figure 5(d-i)).

Interaction between miR-378a-3p and MAPK1

The target genes of miR-378a-3p were predicted using miRDB and TargetScan. The binding sites of
MALAT1 functioned as the sponge of miR-378a-3p.

Figure 3. Knockdown of MALAT1 suppressed the tenogenic differentiation. (a) Transfection efficiency of si-MALAT1. (b, c) Sirius Red staining and OD value measurement of TDSCs on day 7. (d) RT-qPCR was conducted to measure the expression of SCX, Mkx, COL1a1, Fmod, Mmp3, and Thbs4. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 4. MALAT1 functioned as the sponge of miR-378a-3p. (a) Bioinformatic prediction of binding site of miR-378a-3p by MALAT1. (b) Relative luciferase activity of cells after co-transfection with wild type (WT) or mutant (Mut) IncRNA MALAT1 3'-UTR reporter genes and miR-378a-3p mimics. (c) RT-qPCR was conducted to measure the relative expression of miR-378a-3p after si-MALAT1 and oe-MALAT1 transfection. (d) RT-qPCR was conducted to measure the relative expression of miR-378a-3p in the TGFβ1-treated TDSCs. ***P < 0.001.
MAPK1 and miR-378a-3p are shown in Figure 6 (a). Dual-luciferase reporter assay showed that the miR-378a-3p mimic significantly inhibited luciferase activity in TDSCs transfected with WT-MAPK1 instead of MUT-MAPK1 (Figure 6(b)). Knockdown of miR-378a-3p upregulated the expression of MAPK1 and overexpression of miR-378a-3p downregulated the expression of MAPK1 at mRNA and protein levels (Figure 6 (c-d)). In addition, the expression of MAPK1 was upregulated in the TGFβ1 group (Figure 6(e)).

**Overexpression of MAPK1 reversed the effect of miR-378a-3p mimic**

MAPK1 expression was significantly upregulated at both mRNA and protein levels after transfection of MAPK1 in TDSCs (Figure 7(a-b)). Overexpression of miR-378a-3p decreased collagen production, and MAPK1 suppressed the effect of the miR-378a-3p mimic (Figure 7 (c-d)). In addition, compared with the TGFβ1 group, the expression levels of Scx, Mkk, Fmod, Coll1a1, Mmp3 and Thbs4 decreased after transfection with the miR-378a-3p mimic. The overexpression of MAPK1 exhibited the opposite effect (Figure 7(e-j)).

**Overexpression of MALAT1 repaired the damaged tendon tissues in rats**

Finally, we established a rat tendon injury model to explore the function of MALAT1 in vivo. Compared with the CON group, the expression of MALAT1 dramatically decreased in the Model group and oe-MALAT1 group showed significantly increased MALAT1 expression (Figure 8 (a)). In addition, compared with the CON group, the number of cells in the wound region increased in the Model group. The wound region in oe-MALAT1 group exhibited decreased cell numbers (Figure 8(b)). In addition, collagen type I and Thbs4 levels were lower in the Model group compared with the CON group, but higher in the oe-MALAT1 group compared with the Model group (Figure 8(c-d)).

**Discussion**

To date, there have been very few studies on the role of lncRNAs in the regulation of tenogenic differentiation, and the effects of MALAT1 on tenogenic differentiation have not been reported yet. To our knowledge, this study is the first to explore the role of MALAT1. In the current study, we confirmed that MALAT1 acts as a mediator of
Figure 6. Interaction between miR-378a-3p and MAPK1. (a) Bioinformatic prediction of binding site of miR-378a-3p by MAPK1. (b) Relative luciferase activity of cells after co-transfection with wild type (WT) or mutant (Mut) MAPK1 3’-UTR reporter genes and miR-378a-3p mimics. RT-qPCR (c) and western blot (d) was conducted to measure the relative expression of MAPK1 after miR-378a-3p mimic and inhibitor transfection. (e) RT-qPCR was conducted to measure the relative expression of MAPK1 in the TGFβ1-treated TDSCs. ***P < 0.001.

Figure 7. Overexpression of MAPK1 reversed the effect of miR-378a-3p mimic. (a-b) Transfection efficiency of MAPK1 vector. (c-d) Sirius Red staining and OD value measurement of TDSCs on day 7 after miR-378a-3p mimic and MAPK1 vector transfection. (e-j) RT-qPCR was conducted to measure the expressions of SCX, Mkx, COL1a1, Fmod, Mmp3 and Thbs4 after miR-378a-3p mimic and MAPK1 vector transfection. *P < 0.05, **P < 0.01, ***P < 0.001.
tenogenic differentiation and repair by regulating the miR-378a-3p/MAPK1 axis.

The role of IncRNA-mediated epigenetic regulation of transcription in various biological processes has attracted increasing attention [27]. MALAT1 was first discovered as an imprinted gene in non-small cell lung cancer [11]. Previous studies have shown that MALAT1 can specifically recruit members of the SR protein family, and participate in epigenetic and cell cycle regulation [28]. MALAT1 is highly expressed in a variety of tumors and can promote the proliferation, metastasis, and invasion of tumor cells [29,30]. In addition, MALAT1 also plays an important role in angiogenesis [31]. However, the effects of MALAT1 on tenogenic differentiation have not yet been reported. TDSCs are an ideal cell model for studying tendinopathy because of their self-renewal and differentiation abilities [32]. TGF-β1 has been confirmed to be an effective tenogenic inducer that stimulates the expression of tendon related transcription factors and marker genes, such as SCX, Mkk, COL1a1, Fmod, Mmp3, and Thbs4 [33,34]. In this study, we found that MALAT1 is upregulated in TGF-β1-treated TDSCs, and that SCX, Mkk, COL1a1, Fmod, Mmp3, and Thbs4 are downregulated after MALAT1 knockdown. These results indicate that MALAT1 plays an important role in tenogenic differentiation.

Recently, a growing number of studies have demonstrated that IncRNAs regulate various cellular biological activities as competing endogenous (ce) RNA or miRNA sponges. MALAT1 has been shown to be an miRNA sponge for miR-15b-5p in coronary atherosclerotic heart disease [35]. In lung cancer, MALAT1 acts as a ceRNA blocking miR-200a [30]. In addition, MALAT1 regulates the p38 MAPK/NF-κB signaling pathway by interacting with miR-125b, causing worsening of sepsis, heart inflammation, and dysfunction [36]. These findings indicate a negative correlation between MALAT1 and its target miRNAs. In this study, we found that MALAT1 was negatively regulated by miR-378a-3p in TDSCs. Knockdown of miR-378a-3p reversed the effects of si-MALAT1 on the tenogenic differentiation of TDSCs. These results revealed a novel role of MALAT1 in tendon injury. Studies have indicated that mitogen-activated
protein kinase 1 (MAPK1) is a target gene for several miRNAs. Zhu et al. [35] found that MALAT1 suppresses autophagy and apoptosis in endothelial progenitor cells, and promotes cell viability via the miR-15b-5p/MAPK1 axis. Furthermore, MAPK1 was found to be negatively regulated by miRNA-127-5p [37], miR-490-3p [38], miRNA-433-5p [39] and other molecules. However, no studies so far have focused on the role of MAPK1 in tenogenic differentiation. Dual-luciferase reporter assay in this study indicated that MAPK1 shares complementary binding sites with miR-378a-3p. And overexpression of MAPK1 reversed the effects of miR-378a-3p mimic on the tenogenic differentiation of TDSCs. These results indicated that miR-378a-3p inhibits tenogenic differentiation by targeting MAPK1 expression.

Animal experiments are vital for the further study of IncRNAs in tendon injury. Therefore, in this study, we conducted animal experiments involving tendon injury in rats to further explore the role of MALAT1 in tenogenic differentiation. Consistent with the results of experiments on TDSCs, MALAT1 expression was downregulated in tendinopathy rats. Overexpression of MAPK1 significantly increased collagen type I and Thbs4 levels and decreased the number of cells in the wound region of tendinopathy rats. As a result, MALAT1 healed the damaged tendon tissues in rats.

**Conclusion**

In summary, this study demonstrated that MALAT1 heals tendon injuries by inducing the tenogenic differentiation of TDSCs. Exploiting the MALAT1/miR-378a-3p/MAPK1 axis may therefore be a promising avenue for tendon injury treatment.

**Data Availability Statement**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

The project was supported by Shenzhen health committee, subject construction capacity improvement project under grant number SZXJ2018065; Medical Scientific Research Foundation of Guangdong Province under grant number A2018262; the Sanming Project of Shenzhen Health and Family Planning Commission under grant number SZSM201612086.

**Notes on contributor**

All authors participated in the design, interpretation of the studies and analysis of the data and review of the manuscript. Z Z and JQ L drafted the work and revised it critically for important intellectual content; ZQ D and XQ C were responsible for the acquisition, analysis, or interpretation of data for the work; WC L made substantial contributions to the conception or design of the work.

**References**

[1] Figueroa D, Figueroa F, Calvo R. Patellar tendinopathy: diagnosis and treatment. Journal of the American Academy of Orthopaedic Surgeons. 2016;24(12):e184–e192.

[2] Nho SJ, Strauss EJ, Lenart BA, et al. Long head of the biceps tendinopathy: diagnosis and management. Journal of the American Academy of Orthopaedic Surgeons. 2010;18(11):645–656.

[3] Barker N, Bartfield S, Clevers H. Tissue-resident adult stem cell populations of rapidly self-renewing organs. Cell Stem Cell. 2010;7(6):656–670.

[4] Inkson CA, Ehirchiou D, Kilts TM, et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med. 2007;13(10):1219–1227.

[5] Walia B, Huang AH. Tendon stem progenitor cells: understanding the biology to inform therapeutic strategies for tendon repair. J Orthop Res. 2019;37(6):1270–1280.

[6] Wang Y, He G, Guo Y, et al. Exosomes from tendon stem cells promote injury tendon healing through balancing synthesis and degradation of the tendon extracellular matrix. J Cell Mol Med. 2019;23(8):5475–5485.

[7] Costa-Almeida R, Calejo I, Gomes ME. Mesenchymal stem cells empowering tendon regenerative therapies. Int J Mol Sci. 2019;20(12):3002.

[8] Palazzo AF, Koonin EV. Functional long non-coding RNAs evolve from junk transcripts. Cell. 2020;183(5):1151–1161.

[9] Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription. 2014;5(4):e944014–e944014.
[10] Fatica A, Bozzone I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.

[11] Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–8041.

[12] Zhang X, Hamblin MH, Yin K. The long noncoding RNA Malat1: its physiological and pathophysiological functions. RNA Biol. 2017;14(12):1705–1714.

[13] Gao Y, Xiao F, Wang C, et al. Long noncoding RNA MALAT1 promotes osterix expression to regulate osteogenic differentiation by targeting miRNA-143 in human bone marrow-derived mesenchymal stem cells. J Cell Biochem. 2018;119(8):6986–6996.

[14] Che W, Dong Y, Quan HB. RANKL inhibits cell proliferation by regulating MALAT1 expression in a human osteoblastic cell line hFOB 1.19. Cell Mol Biol (Noisy-le-Grand). 2015;61(1):7–14.

[15] Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014;51(4):759–774.

[16] Zhao Z, Sun W, Guo Z, et al. Mechanisms of lncRNA/microRNA interactions in angiogenesis. Life Sci. 2020;1973:254:116900.

[17] Yang X, Yang J, Lei P, et al. LncRNA MALAT1 shuttled by bone marrow-derived mesenchymal stem cells-secreted exosomes alleviates osteoporosis through mediating microRNA-34c/SATB2 axis. Aging (Albany NY). 2019;11(20):8777–8791.

[18] Zhang Y, Wang F, Chen G, et al. LncRNA MALAT1 promotes osteoarthritis by modulating miR-150-5p/AKT3 axis. Cell Biosci. 2019;9(1):54.

[19] Liu Y, Feng L, Xu J, et al. MiR-378a suppresses tenogenic differentiation and tendon repair by targeting at TGF-β2. Stem Cell Res Ther. 2019;10(1):108.

[20] Feldman AT, Wolfe D. Tissue Processing and Hematoxylin and Eosin Staining. New York NY: Springer New York; 2014. p. 31–43.

[21] Mao D, He Z, Xuan W, et al. Effect and mechanism of BDNF/TrkB signaling on vestibular compensation. Bioengineered. 2021;12(2):11823–11836.

[22] Fu Y, Hu X, Gao Y, et al. LncRNA ROR/miR-145-5p axis modulates the osteoblasts proliferation and apoptosis in osteoporosis. Bioengineered. 2021;12(1):7714–7723.

[23] Huang Y, de Boer WB, Adams LA, et al. Image analysis of liver collagen using Sirius red is more accurate and correlates better with serum fibrosis markers than trichrome. Liver Int. 2013;33(8):1249–1256.

[24] Wang M, Guo S, Zhang Y, et al. Remifentanil attenuates sepsis-induced intestinal injury by inducing autophagy. Bioengineered. 2021;12(2):9575–9584.

[25] Zhang H, Fang Z, Guo Y, et al. Long noncoding RNA SNHG10 promotes colorectal cancer cells malignant progression by targeting miR-3690. Bioengineered. 2021;12(1):6010–6020.

[26] Long H, Li Q, Xiao Z, et al. LncRNA MIR22HG promotes osteoarthritis progression via regulating miR-9-3p/ADAMT55 pathway. Bioengineered. 2021;12(1):3148–3158.

[27] Jathar S, Kumar V, Srivastava J, et al. Technological developments in lncRNA biology. Adv Exp Med Biol. 2017;1008:323–329.

[28] Liu L, Tan L, Yao J, et al. Long noncoding RNA MALAT1 regulates cholesterol accumulation in oxLDL-induced macrophages via the microRNA175p/ABC1A axis. Mol Med Rep. 2020;21(4):1752–1760.

[29] Malakar P, Stein I, Saragovi A, et al. Long noncoding RNA MALAT1 regulates cancer glucose metabolism by enhancing mTOR-mediated translation of TCF7L2. Cancer Res. 2019;79(10):2480–2493.

[30] Feng C, Zhao Y, Li Y, et al. LncRNA MALAT1 promotes lung cancer proliferation and gefitinib resistance by acting as a miR-200a sponge. Arch Bronconeumol (Engl Ed). 2019;55(12):627–633.

[31] Sun Z, Ou C, Liu J, et al. YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer. Oncogene. 2019;38(14):2627–2644.

[32] Zhou W, Yang T, Duan J, et al. Magnolol prevents ossified tendinopathy by inhibiting PGE2-induced osteogenic differentiation of TDSCs. Int Immunopharmacol. 2019;70:117–124.

[33] Farhat YM, Al-Maliki AA, Chen T, et al. Gene expression analysis of the pleiotropic effects of TGF-beta1 in an in vitro model of flexor tendon healing. PLoS One. 2012;7(12):e51411.

[34] Guerquin MJ, Charvet B, Nourissat G, et al. Transcription factor EGR1 directs tendon differentiation and promotes tendon repair. J Clin Invest. 2013;123(8):3564–3576.

[35] Zhu Y, Lin X, Chu J, et al. MALAT1/miR-15b-5p/MAPK1 mediates endothelial progenitor cells autophagy and affects coronary atherosclerotic heart disease via mTOR signaling pathway. Aging (Albany NY). 2019;11(4):1089–1109.

[36] Chen H, Wang X, Yan X, et al. LncRNA MALAT1 regulates sepsis-induced cardiac inflammation and dysfunction via interaction with miR-125b and p38 MAPK/NFKappaB. Int Immunopharmacol. 2018;55:69–76.

[37] Zhang C, Wang M-M, Zhang Y, et al. Downregulation of miRNA-127-5p aggravates spinal cord injury through activating MAPK1. Eur Rev Med Pharmacol Sci. 2019;23(24):10617–10622.

[38] Zhang ZY, Gao X-H, Ma M-Y, et al. CircRNA_101237 promotes NSCLC progression via the miRNA-490-3p/MAPK1 axis. Sci Rep. 2020;10(1):9024.

[39] Zhou CL, Li F, Wu X-W, et al. Overexpression of miRNA-433-5p protects acute spinal cord injury through activating MAPK1. Eur Rev Med Pharmacol Sci. 2020;24(6):2829–2835.